Adaptimmune Therapeutics and Alpine Immune Sciences, Inc. have entered a collaboration and license agreement to develop next-generation SPEAR T-cell products incorporating Alpine’s secreted and transmembrane immunomodulatory protein (termed SIP and TIP) technology. This collaboration aims to further enhance Adaptimmune’s efforts to design and develop next-generation SPEAR T-cell therapies. “SPEAR T-cell therapies have demonstrated clinical promise for the treatment of solid tumors. Based on k...